NCT07160075

HIV Prevention With PrEP Among People on Opioid Replacement Therapy

Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: Cara Spence · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest / acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.

Detailed description

In Alberta and Saskatchewan, Canada, HIV acquisition is increasingly and predominantly seen in people who inject drugs (PWID). Less than 2% of this population are utilizing PrEP despite a high level of new infections. The purpose of this study is to assess the feasibility and acceptability of providing oral PrEP and OAT simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest and acceptability of long-lasting injectable options for HIV prevention.

Conditions

• HIV - Human Immunodeficiency Virus

Interventions

Type	Name	Description
BEHAVIORAL	Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs	Simultaneous administration of OAT and oral PrEP (direct observed therapy or home supply) at existing pharmacy-based programs

Timeline

• Start date: 2025-08-28
• Primary completion: 2026-09-01
• Completion: 2027-09-01
• First posted: 2025-09-08
• Last updated: 2025-10-07

Locations

6 sites across 1 country: Canada